Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

June 19, 2024

https://www.globenewswire.com/news-release/2024/06/19/2901079/0/en/Jasper-Therapeutics-Announces-Appointment-of-Svetlana-Lucas-Ph-D-to-its-Board-of-Directors.html

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper’s Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.